MicroRNA 6089 (miR-6089)

MicroRNA 6089 (miR-6089) is a small, non-coding RNA molecule belonging to the microRNA class, functioning as a post-transcriptional regulator of gene expression through its incorporation into the RNA-induced silencing complex (RISC). It binds target mRNAs via imperfect base pairing and typically causes translational inhibition or mRNA degradation[1]. miR-6089 has been identified as a negative regulator of inflammation, particularly through direct inhibition of the TLR4/NF-κB signaling axis. This anti-inflammatory function is implicated in the pathogenesis of allergic rhinitis—where miR-6089 suppresses TLR4-associated cytokine responses and apoptosis in epithelial cells—and in autoimmune conditions such as rheumatoid arthritis, where it targets CCR4 to inhibit proliferation and inflammatory activation of fibroblast-like synoviocytes[3][4][7]. Differential expression of miR-6089 has been observed in human disease tissue, and it is studied as both a mechanistic molecule and potential therapeutic target or biomarker in immune-mediated disease. No direct therapeutic agents targeting miR-6089 are approved; its therapeutic and biomarker roles remain under investigation.

Other names

MIR6089MIR6089-1MIR6089-2hsa-mir-6089-1hsa-mir-6089-2microRNA 6089-1microRNA 6089-2microRNA mir-6089-1microRNA mir-6089-2

miR-6089 functions by downregulating the TLR4 signaling pathway, which leads to decreased production of pro-inflammatory cytokines (such as IL-6, IL-8, and TSLP). It also targets CCR4, thereby regulating cell proliferation and apoptosis in fibroblast-like synoviocytes, and modulates E2F2, influencing osteoblast proliferation and differentiation.